Showing results (371-380 of 390) with videos related to
Sort By:
Pageof 39
Nature Medicine|June 21, 2020
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaDavid Liu, Bastian Schilling, Derek Liu, et al.Nature Genetics|August 29, 2018
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumorsDiana Miao, Claire A Margolis, Natalie I Vokes, et al.Science Translational Medicine|August 28, 2015
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivoLaura R Saunders, Alexander J Bankovich, Wade C Anderson, et al.The New England Journal of Medicine|September 6, 2018
Rituximab plus Lenalidomide in Advanced Untreated Follicular LymphomaFranck Morschhauser, Nathan H Fowler, Pierre Feugier, et al.Plos One|November 12, 2015
Discovery and Characterization of a Potent Interleukin-6 Binding Peptide with Neutralizing Activity In VivoSheila Ranganath, Ashok Bhandari, Nicole Avitahl-Curtis, et al.Nature Medicine|March 5, 2021
Transcriptional mediators of treatment resistance in lethal prostate cancerMeng Xiao He, Michael S Cuoco, Jett Crowdis, et al.The Lancet Regional Health. Western Pacific|October 24, 2025
Policies, resource allocation, and interventions for child and adolescent mental health in low- and middle-income countries in the Western Pacific Region: a scoping reviewJiang Long, Stephanie Zhang, Lingjun Chu, et al.Nature Genetics|April 4, 2018
The long tail of oncogenic drivers in prostate cancerJoshua Armenia, Stephanie A M Wankowicz, David Liu, et al.Science Advances|November 27, 2024
Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanomaGiuseppe Tarantino, Cora A Ricker, Annette Wang, et al.Nature Medicine|May 4, 2021
Evolution of delayed resistance to immunotherapy in a melanoma responderDavid Liu, Jia-Ren Lin, Emily J Robitschek, et al.Pageof 39